HC Wainwright Issues Negative Estimate for DRUG Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a research report issued on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.73) per share for the quarter, down from their previous forecast of ($0.72). HC Wainwright has a “Buy” rating and a $85.00 price objective on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($2.30) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.79) EPS, FY2026 earnings at ($5.63) EPS, FY2027 earnings at ($5.72) EPS, FY2028 earnings at ($5.80) EPS and FY2029 earnings at ($1.70) EPS.

Bright Minds Biosciences (NASDAQ:DRUG) last announced its earnings results on Thursday, February 13th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.24.

Several other research firms have also issued reports on DRUG. Baird R W upgraded shares of Bright Minds Biosciences to a “strong-buy” rating in a research report on Monday, November 25th. Robert W. Baird initiated coverage on shares of Bright Minds Biosciences in a research note on Monday, November 25th. They set an “outperform” rating and a $75.00 price target for the company. Cantor Fitzgerald started coverage on shares of Bright Minds Biosciences in a research note on Friday, January 10th. They set an “overweight” rating for the company. Finally, Piper Sandler started coverage on shares of Bright Minds Biosciences in a research note on Thursday, January 23rd. They set an “overweight” rating and a $93.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Bright Minds Biosciences presently has an average rating of “Buy” and an average target price of $84.33.

Bright Minds Biosciences Trading Down 0.4 %

NASDAQ DRUG opened at $35.99 on Friday. The firm has a market capitalization of $253.37 million, a price-to-earnings ratio of -211.69 and a beta of -6.71. The firm’s 50 day simple moving average is $37.98 and its 200 day simple moving average is $26.48. Bright Minds Biosciences has a 1 year low of $0.93 and a 1 year high of $79.02.

Institutional Investors Weigh In On Bright Minds Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of DRUG. Bank of America Corp DE acquired a new position in shares of Bright Minds Biosciences during the fourth quarter valued at about $173,000. Jane Street Group LLC bought a new stake in Bright Minds Biosciences in the fourth quarter worth about $238,000. Atika Capital Management LLC bought a new stake in Bright Minds Biosciences in the fourth quarter worth about $540,000. Millennium Management LLC bought a new stake in Bright Minds Biosciences in the fourth quarter worth about $1,454,000. Finally, Boothbay Fund Management LLC bought a new stake in Bright Minds Biosciences during the 4th quarter worth approximately $1,606,000. 40.52% of the stock is owned by institutional investors.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.